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Leptomeningeal  carcinomatosis  occurs  in  approximately  5%  of  patients  with  cancer.  The  most  common  cancers 
involving  the  leptomeninges  are  breast,  lung  cancer  and  melanoma.  However,  gastric  adenocarcinoma  has  been  rarely 
reported  with  leptomeningeal  carcinomatosis.  The  presenting  manifestations  are  usually  headache,  visual  disturbances 
and  seizures.  We  report  a  case  of  leptomeningeal  metastasis  that  presented  as  a  gastric  cancer.  A  49-year-old 
woman  was  admitted  to  our  hospital  with  the  symptoms  of  headache  and  melena  for  10  days.  The  endoscopy  showed 
a  thickening  of  the  folds  of  the  stomach  compatible  with  the  diagnosis  of  a  Borrman  type  IV  gastric  cancer.  The  biopsy   
revealed  a  signet  ring  cell  carcinoma.  The  MRI  of  brain  showed  no  abnormal  findings;  however,  the  patient  complained 
of  an  intractable  persistent  headache,  nausea  and  vomiting  on  admission  day  6.  The  cytology  examination  of  the 
cerebrospinal  fluid  supported  the  diagnosis  of  metastatic  signet  ring  cell  carcinoma. 
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INTRODUCTION
Leptomeningeal  carcinomatosis  (LC),  also  called  carcinoma-
tous  leptomeningitis,  neoplastic  (lepto)meningitis,  leptomeningeal 
metastasis,  or  more  commonly  leptomeningeal  seeding,  is  the 
dissemination  and  growth  of  cancer  cells  within  the  leptome-
ningeal  space;  it  is  one  of  the  most  serious  complications  that 
can  occur  in  cancer  patients
1).  The  incidence  of  LC  is  three  to 
8%  of  all  solid  cancers.  LC  is  frequently  found  in  patients  with 
leukemia,  breast  cancer,  lymphoma,  and  lung  cancer
2). 
Gastric  cancer  (GC)  is  one  of  the  most  common  causes  of 
cancer  related  death  in  Asian  countries  including  Korea. 
However,  the  development  of  LC  from  a  GC  is  very  rare.  Kim, 
et  al
3)  reported  that  the  incidence  of  LC  with  GC  was  0.06%  of 
all  cases  of  gastric  cancer.  LC  is  a  more  frequent  manifestation 
of  advanced  or  metastatic  carcinoma  rather  than  associated 
with  early  disease.  It  is  usually  discovered  during  the  treatment 
period  for  the  cancer.  We  report  a  rare  case  with  LC  as  the 
presenting  symptom  and  review  the  medical  literature. 
CASE REPORT
A  49-year-old  woman  was  admitted  to  our  hospital  with 
headache,  dizziness,  easy  fatigability,  and  melena  for  10  days. 
She  looked  pale  and  acutely  ill.  There  were  no  significant 
findings  in  the  medical  history.  On  physical  examination,  she 
was  oriented  to  time,  place  and  person.  Her  vital  signs  were  as 
follows:  a  blood  pressure  of  130/75  mmHg,  a  pulse  rate  of  95 
beats/min  and  a  respiration  rate  of  21  breaths/min.  There  were 
no  focal  neurological  signs  or  abnormal  reflexes.  The  plantar 
reponses  were  flexor.  There  was  no  neck  stiffness  or 
nystagmus.  The  sensory  examination  was  normal.  The  conjunc-
tivae  were  pale,  but  not  icteric.  The  breathing  sounds  were  clear Hong  Gi  Lee,  et  al  :  Gastric  Adenocarcinoma  Presenting  as  Meningeal  Carcinomatosis 305
Figure 1. The gastroscopy showed a discrete ulcer with rugae like 
fold  thickening  on  the  high  body  and  posterior  wall  of  the 
stomach. 
Figure  3.  PAS  (Periodic  acid-Schiff)  staining  reveals  abundant 
intracytoplasmic  mucin  in  the  individual  tumor  cells  (PAS,  ×400).
Figure  4.  Cytology  examination  of  the  CSF  shows  many  floating 
malignant  cells  with  large  mucous  vacuoles  and  displaced 
hyperchromatic  nuclei.
Figure 2. Diffuse infiltration of tumor cells shaped like a signet ring 
with  intracytoplasmic  mucin  pooling,  pushing  the  nuclei  to  the 
periphery  in  the  gastric  mucosa  (H&E,  ×400).
and  the  heart  sounds  were  regular  without  a  murmur. 
Hepatosplenomegaly  was  not  noted.  The  symptoms  were 
slightly  improved  with  conventional  analgesic  agents.  The  MRI 
of  brain  showed  no  abnormalities,  but  the  esophago-
gastroduodenoscopy  showed  thickening  of  the  gastric  folds  on 
the  greater  curvature  of  the  stomach  and  on  the  posterior  wall 
of  the  stomach  compatible  with  a  Borrman  type  IV  gastric 
cancer  (Figure  1).  The  biopsy  revealed  a  signet  ring  cell 
carcinoma  (Figure  2,  3).  The  CT  scan  of  abdomen  and  pelvis 
showed  an  advanced  gastric  cancer  involving  the  posterior  wall 
of  the  lower  body  of  the  stomach;  in  addition,  the  angle  and  the 
antrum  had  extensive  metastatic  lymphadenopathy.  The  patient 
complained  of  an  intractable  persistent  headache  as  well  as 
nausea  and  vomiting  on  admission  day  6.  A  lumbar  puncture 
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The  results  showed  an  elevated  protein  concentration  with 
normal  glucose  content.  There  were  many  mucin-secreting  cells 
and  signet  ring  cell  types,  which  were  strongly  positive  for 
mucicarmin  and  alcian  blue  in  the  CSF  (Figure  4).  Symptomatic 
treatment  was  initiated  with  steroids  and  mannitol.  A  generalized 
tonic  clonic  seizure  developed  on  day  11.  The  patient  became 
stuporous  and  did  not  recover.  Finally,  the  patient  was 
discharged  without  further  medical  treatment. 
DISCUSSION
Since  the  first  report  of  leptomeningeal  carcinomatosis  (LC)  in 
1870,  the  incidence  of  LC  has  been  increasing.  The  incidence  of 
LC  is  three  to  8%  of  all  solid  cancers.  The  most  common 
causes  of  LC  are  breast  and  lung  cancer  and  malignant 
melanoma.  Gastric  cancer  is  the  most  common  cancer  in 
Korea;  however,  LC  associated  with  gastric  cancer  (GC)  is 
relatively  rare.  In  the  Korean  medical  literature,  the  incidence  of 
LC  with  GC  has  been  reported  to  be  0.06%  of  all  gastric 
cancers
3).  Among  cases  with  LC,  GC  is  reported  as  the  most 
frequent  cause  of  cancer  in  Korea
4, 5).  However,  these  results 
are  based  on  the  experience  of  one  institution,  so  these  findings 
may  not  be  generalized  to  the  entire  Korean  population. 
The  clinical  manifestations  of  LC  are  very  variable  and 
depend  on  the  site  of  involvement.  Many  patients  complain  of 
headache,  nausea,  vomiting,  ataxia,  and  have  a  variety  of 
neurological  deficits.  Some  cases  have  presented  with  bilateral 
progressive  blindness
6)  or  bilateral  hearing  loss
7).  LC  is  usually  a 
manifestation  of  advanced  cancer  discovered  during  follow-up 
after  a  cancer  diagnosis;  it  is  rarely  the  presenting  symptom  as 
it  was  in  this  case.  The  median  time  to  the  diagnosis  of  LC, 
from  the  initial  cancer  diagnosis,  is  very  variable;  reports  have 
found  a  76  day
5)  to  17  month
4)  time  interval..  Diagnosis  is  based 
on  cytology  examination  of  the  CSF  and  imaging  studies 
(especially,  magnetic  resonance  imaging  with  gadolinium 
enhancement)
8).  The  CSF  findings  include  an  increased  opening 
pressure,  elevated  protein,  the  presence  of  tumor  markers  (for 
example,  CEA,  CA19-9  in  gastric  cancer),  decreased  glucose, 
and  pleiocytosis.  However,  the  diagnosis  is  frequently  missed  on 
the  first  trial  but  the  diagnosis  rate  increases  by  30%  on  a 
second  one.  In  our  case,  the  definitive  diagnosis  was  achieved 
by  the  first  CSF  cytologic  examination.  Chang,  et  al.  reported  on 
patients  with  breast  cancer  metastasized  to  the  central  nervous 
system  over  20  years.  There  were  43  cases  with  38 
parenchymal  metastases  and  5  leptomeningeal  metastases.  Out 
of  five  LC  patients,  only  one  (20%)  patient  was  confirmed 
cytologically
9).  Pathologically,  poorly  differentiated  adenocar-
cinoma  with  signet  ring  cell  features  is  the  most  frequent  type  of 
LC  associated  with  GC  in  Japan
10)  and  this  is  likely  true  for 
Korea
3).  LC  was  a  more  frequent  finding  in  advanced  disease 
with  or  without  distant  metastases;  it  is  rarely  reported  with  early 
gastric  cancer
11).  Imaging  studies  (MRI  with  gadolinium 
enhancement)  show  abnormalities  in  67%  of  LC  patients
12). 
There  are  several  treatment  options  for  patients  with  LC 
including  intrathecal  (IT)  chemotherapy  with  or  without 
radiotherapy  (RT).  Most  chemotherapeutic  agents  do  not 
penetrate  the  blood-brain  barrier  (BBB),  and  are  given  by  direct 
intrathecal  administration.  Agents  that  can  be  used  for  IT 
chemotherapy  include  methotrexate  (MTX),  cytarabine,  thiotepa, 
and  steroids.  The  benefit  (i.e.  the  prolongation  of  survival) 
achieved  by  IT  chemotherapy  (single  or  multiple  regimens)  in 
LC  patients  continues  to  be  debated.  The  median  survival  of  LC 
is  reported  to  be  four  to  six  months  even  with  aggressive 
therapy.  In  one  study,  the  objective  response  rate  and  median 
survival  of  IT  MTX  were  20%  and  11  weeks;  with  sustained- 
release  cytarabine  they  were  25%  and  15  weeks.  Therefore,  the 
results  did  not  confirm  a  definite  benefit  with  the  IT 
chemotherapy
13).  However,  in  a  Korean  study,  there  was  a 
favorable  outcome  with  combination  IT  chemotherapy, 
compared  to  the  single  IT  chemotherapy
14).  MTX,  one  of  most 
useful  agents  for  IT  chemotherapy,  penetrates  the  blood  brain 
barrier  poorly  in  low  doses,  but  can  penetrate  in  the  higher  dose 
range.  High  dose  intravenous  MTX  (3.5  g/m
2)  injection  showed 
a  28%  partial  response  and  stable  disease  and  44% 
progressive  disease.  The  median  survival  of  patients  with  LC 
(with  or  without  parenchymal  disease)  was  12.6  weeks;  shorter 
than  with  isolated  parenchymal  disease  (25.4  weeks)
15).
The  clinical  risk  factors  that  influence  the  survival  of  patients 
with  LC  are  performance  status,  underlying  malignant  disease 
and  previous  responsiveness  to  anticancer  therapy.  The 
patients  with  disease  that  is  more  advanced,  poor  performance 
status  (PS),  chemoresistant  tumors,  pronounced  neurological 
clinical  findings,  and  a  heavy  pretreatment  status  have  a  poor 
prognosis  and  additional  management  should  be  with  conserva-
tive  treatment
16).  In  our  case,  the  patient  had  a  poor  PS, 
pronounced  abnormal  neurological  clinical  findings  and  a  very 
rapidly  deteriorating  clinical  course. 
REFERENCES
  1) Larson  DA,  Rubenstein  JL,  Mcdermott  MW.  Treatment  of  metastatic 
cancer.  In:  DeVita  JVT,  Hellman  S,  Rosenberg  SA,  eds.  Cancer: 
principles  and  practice  of  oncology.  7th  ed.  p.  2333,  USA,  Lippincott 
Williams  &  Wilkins,  2005 
  2) Lee  JL,  Kang  YK,  Kim  TW,  Chang  HM,  Lee  GW,  Ryu  MH,  Kim  E, 
Oh  SJ,  Lee  JH,  Kim  SB,  Kim  SW,  Suh  C,  Lee  KH,  Lee  JS,  Kim 
WK,  Kim  SH.  Leptomeningeal  carcinomatosis  in  gastric  cancer.  J 
Neurooncol  66:167-174,  2004
  3) Kim  MH.  Intracranial  involvement  by  metastatic  advanced  gastric Hong  Gi  Lee,  et  al  :  Gastric  Adenocarcinoma  Presenting  as  Meningeal  Carcinomatosis 307
carcinoma.  J  Neurooncol  43:59-62,  1999
  4) Park  JO,  Shin  HJ,  Kim  HJ,  Lee  SW,  Jeung  HC,  Kim  SM,  Yoo  NC, 
Chung  HC,  Kim  JH,  Kim  BS,  Min  JS,  Roh  JK.  Leptomeningeal 
carcinomatosis  in  solid  tumors:  clinical  manifestation  and  treatment.  J 
Korean  Cancer  Assoc  33:34-40,  2001
  5) Kim  KW,  Kim  SM,  Kim  JS.  Clinical  features  and  prognosis  of 
leptomeningeal  carcinomatosis.  J  Korean  Neurol  Assoc  7:210-217, 
1989
  6) Kim  SH,  Koh  SB,  Lee  KW.  A  case  of  leptomeningeal  metastasis 
presented  with  bilateral  loss  of  vision.  J  Korean  Neurol  Assoc 
17:780-782,  1999
  7) Wagemakers  M,  Verhagen  W,  Borne  B,  Venderink  D,  Wauters  C, 
Strobbe  L.  Bilateral  profound  hearing  loss  due  to  meningeal 
carcinomatosis.  J  Clin  Neurosci  12:315-318,  2005
  8) Braeuninger  S,  Mawrin  C,  Malfertheiner  P,  Schildhaus  HU,  Seiler  C, 
Dietzmann  K,  Lins  H.  Gastric  adenocarcinoma  with  leptomeningeal 
carcinomatosis  as  the  presenting  manifestation:  an  autopsy  case 
report.  Eur  J  Gastroenterol  Hepatol  17:577-579,  2005
  9) Chang  YS,  Seo  JH,  Lee  R,  Ahn  JB,  Shim  KY,  Gong  SJ,  Lee  HY, 
Rha  SY,  Yoo  NC,  Suh  CO,  Kim  JH,  Rho  JK,  Lee  KS,  Min  JS,  Kim 
BS,  Chung  HC.  Brain  metastasis  and  leptomeningeal  carcinomatosis 
in  breast  cancer.  J  Korean  Cancer  Assoc  30:464-474,  1998
10) Lisenko  Y,  Kumar  AJ,  Yao  J,  Ajani  J,  Ho  L.  Leptomeningeal 
carcinomatosis  originating  from  gastric  cancer:  report  of  eight  cases 
and  review  of  the  literature.  Am  J  Clin  Oncol  26:165-170,  2003
11) Min  KR,  Lee  SK,  Ham  JS,  Rhee  JC,  Lee  MH,  Lee  DH,  Kee  CS, 
Park  KN,  Hong  EK.  A  case  of  leptomeningeal  carcinomatosis  on 
superficial  spreading  carcinoma  of  the  stomach.  Korean  J  Gastro-
intest  Endosc  6:19-23,  1986
12) van  Oostenbrugge  RJ,  Twijnstra  A.  Presenting  features  and  value  of 
diagnostic  procedures  in  leptomeningeal  metastases.  Neurology 
53:382-385,  1999
13) Glantz  MJ,  Jaeckle  KA,  Chamberlain  MC,  Phuphanich  S,  Recht  L, 
Swinnen  LJ,  Maria  B,  LaFollette  S,  Schumann  GB,  Cole  BF,  Howell 
SB.  A  randomized  controlled  trial  comparing  intrathecal  sustained‐
release  cytarabine  (DepoCyt)  to  intrathecal  methotrexate  in  patients 
with  neoplastic  meningitis  from  solid  tumors.  Clin  Cancer  Res 
5:3394-3402,  1999 
14) Kim  DY,  Lee  KW,  Yun  T,  Park  SR,  Jung  JY,  Kim  DW,  Kim  TY,  Heo 
DS,  Bang  YJ,  Kim  NK.  Comparison  of  intrathecal  chemotherapy  for 
leptomeningeal  carcinomatosis  of  a  solid  tumor:  methotrexate  alone 
versus  methotrexate  in  combination  with  cytosine  arabinoside  and 
hydrocortisone.  Jpn  J  Clin  Oncol  33:608-612,  2003
15) Lassman  AB,  Abrey  LE,  Shah  GG,  Panageas  KS,  Begemann  M, 
Malkin  MG,  Raizer  JJ.  Systemic  high-dose  intravenous  methotrexate 
for  central  nervous  system  metastases.  J  Neurooncol  78:255-260, 
2006
16) Pavlidis  N.  The  diagnostic  and  therapeutic  management  of  leptom-
eningeal  carcinomatosis.  Ann  Oncol  15(Suppl  4):iv285-iv291,  2004